multiple endocrine neoplasia

in review 4 min read Updated 2026-11-19
multiple endocrine neoplasia

All MEN syndromes are autosomal dominant — when one component tumour appears (especially in a young patient or with multigland/multifocal disease), screen for the others and offer germline genetic testing. MEN1 (MEN1 / menin) = parathyroid (~90–100%, earliest), pancreatic/duodenal NETs (gastrinoma, insulinoma, non-functioning — leading cause of death), and pituitary (prolactinoma commonest). MEN2 (RET) = medullary thyroid cancer (~100%) + phaeochromocytoma (+ PHPT in MEN2A; marfanoid habitus + mucosal neuromas in MEN2B). In MEN2, always exclude and resect phaeochromocytoma before thyroid or parathyroid surgery.


comparison of MEN syndromes

featureMEN1 (“3 Ps”)MEN2AMEN2B
gene & mechanismMEN1 (11q13; menin tumour suppressor; loss of function)RET proto-oncogene (gain of function; e.g., exon 10/11, codon C634)RET proto-oncogene (gain of function; M918T in >95%, or A883F)
inheritanceautosomal dominantautosomal dominantautosomal dominant (~75% de novo)
primary hyperparathyroidism~90–100% (earliest, multigland hyperplasia; onset ~20–25 y)20–30%absent
medullary thyroid cancerabsent~95–100% (onset childhood–adult)100% (very aggressive; infancy)
phaeochromocytomarare (<1%)~50% (often bilateral)~50% (often bilateral)
pituitary adenoma30–40% (prolactinoma #1, GH, ACTH, non-functioning)absentabsent
enteropancreatic NETs30–70% (non-functioning, gastrinoma, insulinoma, VIPoma, glucagonoma)absentabsent
other hallmark featuresfacial angiofibromas, collagenomas, lipomas, thymic/bronchial carcinoids, adrenal cortical tumourscutaneous lichen amyloidosis, Hirschsprung diseasemucosal neuromas (lips, tongue, eyelids), marfanoid habitus, intestinal ganglioneuromatosis

MEN1 diagnosis, management, and surveillance (ES 2012)

when to test for germline MEN1 mutation

  • Patient with ≥2 MEN1-associated tumours (parathyroid, pituitary, enteropancreatic NET), or 1 MEN1 tumour in a first-degree relative of a known MEN1 patient
  • Young PHPT (<40 y) with multigland parathyroid disease (or recurrent PHPT)
  • Any patient with gastrinoma or multiple pancreatic NETs at any age
  • First-degree relatives of a confirmed MEN1 mutation carrier (offer genetic counselling and predictive testing from childhood)

organ-specific management

  • Primary hyperparathyroidism: typically involves all four glands — open bilateral neck exploration with subtotal parathyroidectomy (3.5 glands) or total parathyroidectomy with forearm autotransplantation (plus consider concurrent transcervical thymectomy to prevent thymic carcinoid); minimally invasive single-glandectomy has high recurrence
  • Enteropancreatic NETs (leading cause of MEN1-related mortality):
    • Gastrinoma (Zollinger–Ellison syndrome): refractory peptic ulcers, diarrhoea, elevated fasting gastrin (hold PPI if safe or confirm gastric pH <2); usually multiple small duodenal submucosal lesions → high-dose PPIs are mainstay for most patients (curative surgery rarely achieved without pancreaticoduodenectomy; resect pancreatic gastrinomas selectively in expert centres)
    • Insulinoma: fasting hypoglycaemia (Whipple triad) → surgical resection is first-line and usually curative
    • Non-functioning pancreatic NETs: consider surgery if >1–2 cm or showing significant growth over 6–12 months; for advanced progressive well-differentiated NETs, options include somatostatin analogues, everolimus, sunitinib, or PRRT
  • Pituitary adenomas: treat per sporadic guidelines (cabergoline first-line for prolactinoma, transsphenoidal surgery for GH/ACTH/mass effect)
  • Surveillance in MEN1 mutation carriers:
    • Annual biochemistry: serum calcium, PTH, prolactin, IGF-1, fasting GI hormones (gastrin, glucose/insulin/chromogranin A)
    • Periodic imaging: pancreas/adrenal MRI or CT and pituitary MRI at baseline then every 1–3 years; chest CT/MRI every 1–2 years for thymic/bronchial carcinoids; upper endoscopy every 3 years if hypergastrinaemia (gastric type II ECLomas)

MEN2 and medullary thyroid cancer (ATA 2015)

germline RET testing and risk-stratified thyroidectomy

  • Every patient with apparently sporadic medullary thyroid cancer must receive germline RET testing (1–7% harbour occult hereditary MEN2); offer predictive testing to all first-degree relatives of RET carriers
  • ATA hereditary MTC risk categories guide timing of prophylactic total thyroidectomy:
    • ATA-HST (highest risk — RET M918T, MEN2B): total thyroidectomy in the first year of life (often first months)
    • ATA-H (high risk — RET C634 or A883F): total thyroidectomy at age 5 years (or earlier if serum calcitonin rises)
    • ATA-MOD (moderate risk — all other RET mutations): annual neck US + serum calcitonin starting at age 5 years; operate when calcitonin becomes elevated (or earlier based on family preference)

phaeochromocytoma and parathyroid rules in MEN2

exclude and resect phaeochromocytoma first

Every patient with MEN2A or MEN2B must have phaeochromocytoma excluded (plasma free or 24-h urine fractionated metanephrines) before any thyroid/parathyroid surgery or pregnancy. If phaeo coexists with MTC or PHPT, resect the phaeochromocytoma first after 7–14 days of α-blockade to prevent fatal intraoperative hypertensive crisis.

  • Phaeochromocytoma surveillance: start annual metanephrines at age 11 (ATA-HST and ATA-H) or age 16 (ATA-MOD); consider cortex-sparing subtotal adrenalectomy in bilateral hereditary phaeo to avoid lifelong adrenal insufficiency
  • PHPT surveillance (MEN2A only): screen annual serum calcium (+ PTH) at age 11 (ATA-H) or age 16 (ATA-MOD); resect only visibly enlarged parathyroid glands (or subtotal/total + autograft if all four enlarged)
  • MTC biochemical markers: measure both calcitonin and CEA concurrently (CEA disproportionate to calcitonin signals dedifferentiated/aggressive disease); MTC cells lack NIS, so radioactive iodine has no role

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

Suggest a correction multiple endocrine neoplasia